| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in IONS over the last quarter tilts toward selling: insiders offloaded a net 196,094 shares worth roughly $15.4M.
Classified under Biotechnology (Health Care sector), IONS's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 156.0K | $8.82M | - | |
| CEO | 99.9K | $5.65M | - | |
| CFO | 82.7K | $4.68M | - | |
| VP | 74.4K | $4.21M | - | |
| VP | 69.7K | $3.94M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 2, 2024 | Monia Brett P60 | Chief Executive Officer | Sell | 23,501 | $49.37 | $1,160,303.12 | -11.9% | -13.4% | -35.9% | |
| Feb 2, 2024 | Swayze Eric63 | EVP Research | Sell | 12,680 | $51.63 | $654,709.40 | -15.9% | -13.4% | -35.9% | |
| Jan 25, 2024 | O'Neil Patrick R.57 | EVP CLO &General Counsel | Sell | 6,450 | $51.75 | $333,787.50 | -12.1% | -17.7% | -32.6% | |
| Jan 25, 2024 | Monia Brett P60 | Chief Executive Officer | Sell | 2,285 | $51.75 | $118,248.75 | -1.5% | -17.7% | -32.6% | |
| Jan 17, 2024 | Monia Brett P60 | Chief Executive Officer | Sale+OE | 32,059 | $50.42 | $1,616,318.60 | -17.2% | -19.0% | -37.1% | |
| Jan 17, 2024 | Cadoret-Manier Onaiza53 | EVP, Chf Gl Pdt Str &Oper Ofc | Sale+OE | 5,564 | $50.42 | $280,520.19 | -14.1% | -19.0% | -37.1% | |
| Jan 17, 2024 | O'Neil Patrick R.57 | EVP CLO &General Counsel | Sale+OE | 7,744 | $50.42 | $390,429.25 | -12.7% | -19.0% | -37.1% | |
| Jan 17, 2024 | Birchler Brian55 | EVP, Corp And Development Ops | Sale+OE | 4,497 | $50.42 | $226,725.25 | -9.2% | -19.0% | -37.1% | |
| Jan 17, 2024 | Swayze Eric63 | EVP Research | Sale+OE | 6,305 | $50.42 | $317,879.19 | -12.7% | -19.0% | -37.1% | |
| Jan 17, 2024 | Schneider Eugene64 | EVP, Chf Clinical Develop Ofcr | Sale+OE | 5,482 | $50.42 | $276,385.99 | -10.3% | -19.0% | -37.1% |